Internal Reference Number: FOI_7463
Date Request Received: 04/10/2023 00:00:00
Date Request Replied To: 20/10/2023 00:00:00
This response was sent via: By Email
Request Summary: Ophthalmology drugs
Request Category: Private Individuals
| Question Number 1: For the 4 months from May to August 2023, how many patients received the following intra-vitreal treatments for any eye condition: Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab 鈥� Lucentis Ranibizumab 鈥� Ongavia | |
| Answer To Question 1: Aflibercept 627 Bevacizumab <5 Brolucizumab 0 Dexamethasone 9 Faricimab 278 Ranibizumab 鈥� Lucentis <5 Ranibizumab 鈥� Ongavia 0 | |
| Question Number 2: For the patients above, how many were new to intra-vitreal treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments. Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab 鈥� Lucentis Ranibizumab 鈥� Ongavia | |
| Answer To Question 2: Aflibercept 62 Bevacizumab <5 Brolucizumab 0 Dexamethasone <5 Faricimab 41 Ranibizumab 鈥� Lucentis 0 Ranibizumab 鈥� Ongavia 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at 黑料网 District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
